Take Homes in Lung Cancer
Take Homes in Lung Cancer
Source/Disclosures
Source:

Healio Interview

Disclosures: Stevenson reports receiving clinical trial research funding from Bristol-Meyers Squibb and Merck.
October 06, 2020
1 min watch
Save

VIDEO: Don’t leave PKI analysis behind in lung cancer immunotherapy

Source/Disclosures
Source:

Healio Interview

Disclosures: Stevenson reports receiving clinical trial research funding from Bristol-Meyers Squibb and Merck.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.

“Pharmacokinetics is worthy of a bit more study in immunotherapies because ...some of [us] think that pharmacokinetics might not matter as much as they do with chemo-therapeutics,” Stevenson said. “But it may turn out that PKI analyses are important for immunotherapies as well.”

References:

  • Barlesi F, et al. Abstract LBA53. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.